Browsing by Author "Karakuş, Volkan"
Now showing items 1-3 of 3
-
Acute lymphoblastic leukemia in routine practice: A Turkish multicenter study
Çiftçiler, Rafiye; Sevindik, Ömür Gökmen; Tekgündüz, Ali İrfan Emre; Erkurt, Mehmet Ali; Vural, Filiz; Turgut, Burhan; Kaynar, Leylagül; Payzın, Bahriye; Doğu, Mehmet Hilmi; Karakuş, Volkan; Altuntaş, Fevzi; Büyükaşık, Yahya; Demirkan, Fatih (Turkish Society of Hematology, 2019)Objective: Significant developments occurred in the clinical management of acute lymphoblastic leukemia (ALL) in adults in recent decades. However, treatment results are still not satisfactory, especially in routine practice. ... -
Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: A multicenter experience
Gören Şahin, Deniz; Akay, Olga Meltem; Keklik, Muzaffer; Okan, Vahap; Karakuş, Abdullah; Demir, Cengiz; Erkurt, Mehmet Ali; İlkkılıç, Kadir; Yıldırım, Rahşan; Akgün Çağlıyan, Gülsüm; Aksu, Salih; Doğu, Mehmet Hilmi; Dal, Mehmet Sinan; Karakuş, Volkan; Gemici, Ali İhsan; Terzi, Hatice; Kelkitli, Engin; Şıvgın, Serdar; Ünal, Ali; Yılmaz, Mehmet; Ayyıldız, Orhan; Korkmaz, Serdal; Eser, Bülent; Altuntaş, Fevzi (Springer, 2021)The aim of this study is to collect paroxysmal nocturnal hemoglobinuria (PNH) patient data from hematology centers all over Turkey in order to identify clinical features and management of PNH patients. Patients with PNH ... -
A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
Gemici, Aliihsan; Özkalemkaş, Fahir; Doğu, Mehmet Hilmi; Tekinalp, Atakan; Alacacıoğlu, İnci; Güney, Tekin; İnce, İdris; Gedük, Ayfer; Akgün Çağlıyan, Gülsüm; Maral, Senem; Serin, İstemi; Gündüz, Eren; Karakuş, Volkan; Beköz, Hüseyin Saffet; Eren, Rafet; Pınar, İbrahim Ethem; Güneş, Ahmet Kürşad; Sargın, Fatma Deniz; Sevindik, Ömür Gökmen (CIG Media Group, 2021)Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients ...
